Sort
15,273 grants matching “antimicrobial resistance”
Genetic basis of metabolite production against clinically-derived pathogens
$439,600Hans Wildschutte · Bowling Green State University · R15 · FY2021 · GM
Virulence mechanisms of group A streptococcal toxins
$439,583Michael R Wessels · Boston Children'S Hospital · R56 · FY2014 · AI
Antimicrobial Use in Dialysis Units
$439,414Erika M D'agata · Rhode Island Hospital · R18 · FY2015 · HS
Rapid and Expandable Nucleic Acid Platform to Detect *
$439,403Public Health Research Institute · U01 · FY2005 · AI
A new allograft that promotes long-term, infection-free skeletal repair
$439,379Noreen J Hickok · Thomas Jefferson University · R01 · FY2009 · DE
Second Messenger Nucleotides of Enterococcus faecalis
$439,107Jose A Lemos · University Of Florida · R56 · FY2022 · AI
Neutrophil-intrinsic role of SLC11A1/NRAMP1 in control of bacterial infection
$438,977Renee M. Tsolis · University Of California At Davis · R01 · FY2021 · AI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics
$438,783David Elihu Greenberg · Ut Southwestern Medical Center · R33 · FY2018 · AI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.
$438,766Jason W. Rosch · Broad Institute, Inc. · U19 · FY2022 · AI
Quinolone and multidrug resistance in Staphylococcus aureus
$438,750David C Hooper · Massachusetts General Hospital · R37 · FY2008 · AI
Effects of Probiotics in Patients with Cystic Fibrosis
$438,645Patricia L Hibberd · Massachusetts General Hospital · U01 · FY2010 · AT
Mechanistic Investigations of Host Defense Metallopeptide Interactions with Bacterial Cell Membranes
$438,580Myriam Cotten · College Of William And Mary · R15 · FY2019 · GM
CAREER: A Multi-phase Biosensing Approach towards Point-of-Care Evaluation of Pseudomonas aeruginosa Virulence in Infected Chronic Wounds
$438,544Jordon Gilmore · Clemson University · · FY2024 · ENG
Synergistic killing of bacterial pathogens by histones
$438,448Albert Siryaporn · University Of California-Irvine · R01 · FY2022 · AI
Novel antibacterial agents resistant to inactivation by polyelectrolytes
$438,243Paul A Janmey · University Of Pennsylvania · R01 · FY2009 · HL
Pattern Recognition Receptors and Autophagy in Mtb Control in AIDS
$438,075Vojo P Deretic · University Of New Mexico · R01 · FY2010 · AI
Chemical Biological and Genomic Approaches to Bacterial Virulence Regulation
$438,075Deborah T Hung · Massachusetts General Hospital · R01 · FY2010 · AI
Quinolone and multidrug resistance in Staphylococcus aureus
$438,075David C Hooper · Massachusetts General Hospital · R37 · FY2010 · AI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
$438,075Robert D Moir · Massachusetts General Hospital · R01 · FY2014 · AI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
$438,075Robert D Moir · Massachusetts General Hospital · R01 · FY2012 · AI
Novel antibiotics that trap Holliday junctions
$438,021San Diego State University · R01 · FY2005 · AI
HLA-E restricted T-cell immunity in Mycobacterium tuberculosis infection
$437,942Tom Ottenhoff · Leiden University Medical Center · R01 · FY2019 · AI
Uncultured bacteria for the discovery of novel antimicrobials
$437,659Amy Lynn Spoering · Northeastern University · P01 · FY2019 · AI
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability
$437,644Arnold S Bayer · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2021 · AI
Intestinal 5-HT Transporter: A novel therapeutic target for GI disorders
$437,622Ravinder K Gill · University Of Illinois At Chicago · R01 · FY2019 · DK